Sara Bouberhan, MD
Hematology & Oncology · Boston, MANPI 1487929634
Payments from drug & device makers
What this record shows
This record is dominated by education: $69 of the $111 with a category attached, or 62.4%. 3 manufacturers reported payments, led by AstraZeneca at 39.1% of the total. That places this record below the midpoint for hematology & oncology clinicians in MA, where the typical reported total is $856.
Across 3 payments — averaging $36.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$43
- Genmab U.S., Inc.$42
- Merck$26
Across 229 payments — averaging $15,879 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$2.3M
- AstraZeneca$996K
- Novartis$256K
- Clovis Oncology, Inc.$108K
- AbbVie$13K
- Immunogen, Inc.$81
What the payments were for
- Food & beverage$4238%
- Education$6962%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 1 | $43 |
| Genmab U.S., Inc. | 1 | $42 |
| Merck | 1 | $26 |
How this compares
$111 in reported general payments places this provider in the 20th percentile of 374 hematology & oncology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LynparzaOlaparib | 26 | $318,492 |
| ZejulaNiraparib Tosylate | 12 | $222,177 |
| EliquisApixaban | 36 | $27,373 |
| Dexamethasone | 81 | $1,514 |
| Prednisolone Acetate | 11 | $688 |
| Olanzapine | 28 | $424 |
| Ondansetron Hcl | 68 | $367 |
| Oxycodone Hcl | 27 | $361 |
| Prochlorperazine Maleate | 32 | $334 |
| Gabapentin | 38 | $253 |
| Prednisone | 18 | $70 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 11 | $69 |
| Lorazepam | 35 | $69 |
| Montelukast Sodium | 11 | $46 |
| Amlodipine Besylate | 12 | $30 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaLynparza | $43 | $318,49226 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 374 hematology & oncology providers in Massachusetts.
Other hematology & oncology in Boston
- David ScaddenBoston$2.6M
- Sara TolaneyBoston$799K
- Matthew DavidsBoston$693K
- Julio HajdenbergBoston$583K
- Paul RichardsonBoston$523K
- Seth WanderBoston$464K
- Corey CutlerBoston$454K
- Hanny Al-SamkariBoston$412K
- Rupal BhattBoston$380K
- Matthew Vander HeidenBoston$355K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.